HUMA

Humacyte Inc

Add to Watchlist

Advanced Chart

1.170

-0.02(-1.681%)1D

Line

Candle

YTD

High

1.170

Open

1.150

VWAP

1.14

Vol

862.80K

Mkt Cap

222.85M

Low

1.130

Amount

986.30K

EV/EBITDA(TTM)

Total Shares

119.08M

236.26M

EV/OCF(TTM)

P/S(TTM)

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

-0.117

-51.04%

-0.122

-143.75%

-0.134

-16.25%

Estimates Revision

The market is revising Downward the revenue expectations for Humacyte, Inc. (HUMA) for FY2025, with the revenue forecasts being adjusted by -0.13% over the past three months. During the same period, the stock price has changed by -37.77%.

Revenue Estimates for FY2025

Revise Downward

-0.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.55%

In Past 3 Month

Stock Price

Go Down

-37.77%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.170

Low

3.00

Averages

6.00

High

14.00

Current: 1.170

Low

3.00

Averages

6.00

High

14.00

Benchmark

Bruce Jackson

Buy

downgrade

$14 -> $11

2025-11-13

New

Reason

Benchmark

Bruce Jackson

Price Target

$14 -> $11

2025-11-13

New

downgrade

Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Humacyte to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte's new shares for the target drop but believes the company's customer base continues to build.

Barclays

Matt Miksic

Overweight

initiated

$3.50

2025-08-27

Reason

Barclays

Matt Miksic

Price Target

$3.50

2025-08-27

initiated

Overweight

Reason

Barclays analyst Matt Miksic initiated coverage of Humacyte with an Overweight rating and $3.50 price target. The company is in the early stages of launching Symvess in vascular trauma, which is the first of four initial indications for its acellular tissue engineered vessel, the analyst tells investors in a research note. Barclays says the initial indication addresses significant challenges and costs associated with the care of patients suffering from vascular trauma. It sees potential sales of over $600M.

H.C. Wainwright

Buy

downgrade

$4 -> $3

2025-08-12

Reason

H.C. Wainwright

Price Target

$4 -> $3

2025-08-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Humacyte to $3 from $4 and keeps a Buy rating on the shares. The firm says the company's July sales growth suggests potential momentum.

TD Cowen

Buy

downgrade

2025-08-12

Reason

TD Cowen

Price Target

2025-08-12

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Humacyte to $3.50 from $5 and keeps a Buy rating on the shares. The firm said the Symvess launch continues to advance with 13 hospital VAC approvals now in hand up from 5 in 1Q'25. Cowen said they are encouraged by this recent improvement in commercial traction and expect sequential revenue growth throughout 2H'25 and 2026.

Benchmark

analyst

Buy

downgrade

$17 -> $14

2025-05-14

Reason

Benchmark

analyst

Price Target

$17 -> $14

2025-05-14

downgrade

Buy

Reason

Benchmark lowered the firm's price target on Humacyte to $14 from $17 and keeps a Buy rating on the shares. Humacyte launched Symvess in February and generated its first commercial product revenue during Q1, notes the analyst, who believes the company is poised to gain significant share for surgical procedures requiring vascular grafts and notes that the new product pipeline continues to move forward.

H.C. Wainwright

Buy

initiated

2025-05-14

Reason

H.C. Wainwright

Price Target

2025-05-14

initiated

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Humacyte Inc (HUMA.O) is -2.29, compared to its 5-year average forward P/E of -5.85. For a more detailed relative valuation and DCF analysis to assess Humacyte Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.85

Current PE

-2.29

Overvalued PE

-1.56

Undervalued PE

-10.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.28

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.66

Undervalued EV/EBITDA

-8.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

757.02

Current PS

1.19

Overvalued PS

2102.94

Undervalued PS

-588.91